Efficacy and Safety Study of the Fixed-dose Combination of Olmesartan + Indapamide When Compared to the Isolated Drugs in the Treatment of Hypertension.

Inclusion Criteria:

• Have signed the informed consent form;
• Participants of both genders aged ≥ 18 years;
• Essential hypertension based on a Diastolic Blood Pressure (DBP) > 90 mmHg and < 110mmHg;
• Patients with no treatment or on antihypertensive therapy taking up to twoanti-hypertensives;
• Possibility of discontinuing previous antihypertensive medication during the washoutperiod.

Exclusion Criteria:

• Essential hypertension based on a Diastolic Blood Pressure (DBP) ≥ 110mmHg andSystolic Blood Pressure (SBP) ≥ 180 mmHg;
• Secondary hypertension;
• Participants with Body Mass Index (BMI) > 35 Kg/m2;
• Non-controlled types 1 and 2 diabetes mellitus (HbA1 > 8,5%);
• Myocardial infarction, coronary surgery or coronary angioplasty with or without stentplacement, in the last 6 months;
• Unstable angina;
• Participants with coronary heart disease taking beta-blockers;
• Clinically manifest heart failure;
• History of cardiac arrhythmia;
• Moderate and severe heart valve disease;
• Stroke or transient ischemic attack in the last 6 months;
• Chronic disease of any nature that contraindicates the participant's participationaccording to the investigator's judgment, in particular renal failure with glomerularfiltration rate < 45 ml/min, serum potassium levels ≥ 5,5 mEq/L or ≤ 3,5 mEq/L,hepatopathies, or SGOT, SGPT or bilirubin levels 3 times above the normal upper limit,and blood dyscrasias;
• Known allergies or contraindication to the use of the study medication components;
• Female participants who are pregnant, breastfeeding or who want to become pregnant;
• COVID-19 symptoms;
• Post COVID-19 syndrome with cardiovascular impairment;
• Subjects who have participated in other study within the 12 months prior to screening (unless benefit is justified by the researcher).